{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-044128","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2021-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.266623+00:00","generated_at":"2026-06-29T11:32:53.225631+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"PMV Pharma Q2 2021 net loss $24.5M; cash $339M; PC14586 trial enrollment ongoing","bullets":["Net loss for H1 2021 was $24.5M vs $15.2M in H1 2020.","Cash, cash equivalents & marketable securities $339.0M at June 30, 2021.","R&D expenses $15.2M (H1 2021) vs $11.8M (H1 2020) on PC14586 development.","Continued enrollment in Phase 1/2 trial of p53 Y220C reactivator PC14586.","Activated 12 clinical trial sites across leading US oncology centers."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-044128","json":"https://secwatch.observer/filing/0001564590-21-044128.json","markdown":"https://secwatch.observer/filing/0001564590-21-044128.md","text":"https://secwatch.observer/filing/0001564590-21-044128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000156459021044128/0001564590-21-044128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000156459021044128/pmvp-8k_20210813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T11:32:53.225631+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}